Neurocrine Biosciences, Inc.

Jurisdiction

United States

LEI

549300FECER0XBN49756

ISIN

US64125C1099

(NBIX)

Sectors

Scores

InsiderPie Expert Score: trending_flat 55 / 100
Better than peer group:: 50 / 100
Fair value (Benjamin Graham formula): €161.69 35.6% undervalued
Financial strength (Piotroski F-Value): 5 / 9
Fundamental strength relative to industry (Mohanram G-Value): 7 / 7

Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Read full profile

Fundamentals

Net revenue: €2.15B
Gross margin: 98.5%
EBIT: €424.71M
EBIT margin: 19.7%
Net income: €298.84M
Net margin: 13.9%

Statement period: July 1, 2024 - June 30, 2025 (published July 30, 2025)

Estimates

Fiscal Year	Net revenue	Net income
2026	€2.77B +28.5%	€593.43M +98.6%
2027	€3.07B +10.9%	€748.76M +26.2%
2028	€3.42B +11.3%	€969.12M +29.4%

Dividends

No dividend payouts

Insider Transactions

Name	Title	Transaction Date	Shares	Price	Value
GORMAN KEVIN CHARLES	N/A	August 7, 2025	-106K	$126.41	-$13.44M

Congress transactions

Name	Transaction date	Value
Lisa McClain	August 13, 2025	$1.00K–$15.00K
Lisa McClain	August 13, 2025	$1.00K–$15.00K

Earnings Calls

Latest earnings call: October 31, 2023

Investor transactions

Name	Shares	Value	Last change	Change type
Peter Brown	2.5M	$276.80M	+13K	Buy
George Soros	240K	$26.52M	+40K	Buy
Ray Dalio	87K	$9.65M	-245K	Sell